VF
FATE icon

Virtu Financial’s Fate Therapeutics FATE Stock Holding History

Virtu Financial’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$92K Buy
76,561
+7,690
+11% +$9.36K ﹤0.01% 1209
2025
Q4 		$68K Buy
+68,871
New +$82.7K ﹤0.01% 1268
2025
Q3 		– Sell
-100,879
Closed -$113K – 1655
2025
Q2 		$113K Buy
+100,879
New +$117K 0.01% 1026
2023
Q1 		– Sell
-14,594
Closed -$147K – 1677
2022
Q4 		$147K Buy
14,594
+1,921
+15% +$36.1K 0.02% 825
2022
Q3 		$284K Buy
+12,673
New +$366K 0.03% 679
2021
Q2 		– Sell
-11,759
Closed -$970K – 1678
2021
Q1 		$970K Buy
+11,759
New +$1.13M 0.07% 264
2018
Q2 		– Sell
-16,521
Closed -$161K – 2116
2018
Q1 		$161K Sell
16,521
-1,730
-9% -$16.6K 0.01% 1443
2017
Q4 		$112K Sell
18,251
-242
-1% -$1.08K 0.01% 1878
2017
Q3 		$73K Buy
+18,493
New +$62.9K ﹤0.01% 2151

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial's FATE Position: Q1 2026 in Review

Virtu Financial increased its Fate Therapeutics (FATE) stake by 11% in Q1 2026, buying an estimated $9.36K and bringing the position to 76,561 shares worth $92K. The position accounts for ﹤0.01% of the portfolio, ranked #1209.

Virtu Financial first reported a position in FATE in Q3 2017 and has held it in 9 quarters since. The position peaked at $970K in Q1 2021. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Virtu Financial held 76,561 shares of Fate Therapeutics worth $92K as of Q1 2026.
  • Virtu Financial bought 7,690 Fate Therapeutics shares in Q1 2026, an estimated $9.36K.
  • Fate Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q1 2026, its #1209 holding.
  • Virtu Financial first reported a position in Fate Therapeutics in Q3 2017 and has held it in 9 quarters since.
  • Virtu Financial's Fate Therapeutics position peaked at $970K in Q1 2021.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.